Laurel Wealth Advisors (North Carolina)’s Arcturus Therapeutics ARCT Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-125	Closed	-$2K	–	541
2022 Q2	$2K	Hold	125	–	–	﹤0.01%	523
2022 Q1	$3K	Hold	125	–	–	﹤0.01%	527
2021 Q4	$5K	Hold	125	–	–	﹤0.01%	475
2021 Q3	$6K	Hold	125	–	–	﹤0.01%	449
2021 Q2	$4K	Buy	125 +75	+150%	+$2.54K	﹤0.01%	560
2021 Q1	$2K	Buy	+50	New	+$2.98K	﹤0.01%	593

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ARCT Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 125 shares — an estimated $2K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in ARCT in Q1 2021 and held it in 6 quarters. The position peaked at $6K in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 125 Arcturus Therapeutics shares in Q3 2022, an estimated $2K.
Laurel Wealth Advisors (North Carolina) first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 6 quarters.
Laurel Wealth Advisors (North Carolina)'s Arcturus Therapeutics position peaked at $6K in Q3 2021.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.